Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200017911
    Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
    Type: Application
    Filed: August 10, 2018
    Publication date: January 16, 2020
    Inventor: D. Travis Wilson
  • Patent number: 10525098
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 7, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20200000870
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Application
    Filed: February 8, 2019
    Publication date: January 2, 2020
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • Publication number: 20190388493
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Application
    Filed: May 29, 2019
    Publication date: December 26, 2019
    Inventor: D. Travis Wilson
  • Publication number: 20190374596
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogues of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).
    Type: Application
    Filed: May 14, 2019
    Publication date: December 12, 2019
    Applicant: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20190365845
    Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
    Type: Application
    Filed: October 23, 2018
    Publication date: December 5, 2019
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20190365846
    Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 5, 2019
    Applicant: Stealth BioTherapeutics Corp
    Inventor: D. Travis Wilson
  • Publication number: 20190358286
    Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: November 15, 2018
    Publication date: November 28, 2019
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20190343913
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Application
    Filed: April 22, 2019
    Publication date: November 14, 2019
    Applicant: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20190336566
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: December 5, 2018
    Publication date: November 7, 2019
    Inventors: Kenneth Borow, D. Travis Wilson
  • Publication number: 20190328822
    Abstract: The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.
    Type: Application
    Filed: November 28, 2018
    Publication date: October 31, 2019
    Applicant: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20190276494
    Abstract: The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 12, 2019
    Inventor: D. Travis Wilson
  • Patent number: 10322159
    Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 18, 2019
    Assignees: STEALTH BIOTHERAPEUTICS CORP, GOOD SAMARITAN INSTITUTE FOR RESEARCH AND EDUCATION
    Inventors: D. Travis Wilson, Kenneth Borow, Robert A. Kloner, Sharon Hale
  • Patent number: 10311878
    Abstract: Incorporation of an exogenous large-vocabulary model into rule-based speech recognition is provided. An audio stream is received by a local small-vocabulary rule-based speech recognition system (SVSRS), and is streamed to a large-vocabulary statistically-modeled speech recognition system (LVSRS). The SVSRS and LVSRS perform recognitions of the audio. If a portion of the audio is not recognized by the SVSRS, a rule is triggered that inserts a mark-up in the recognition result. The recognition result is sent to the LVSRS. If a mark-up is detected, recognition of a specified portion of the audio is performed. The LVSRS result is unified with the SVSRS result and sent as a hybrid response back to the SVSRS. If the hybrid-recognition rule is not triggered, an arbitration algorithm is evoked to determine whether the SVSRS or the LVSRS recognition has a lesser word error rate. The determined recognition is sent as a response to the SVSRS.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: June 4, 2019
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Travis Wilson, Salman Quazi, John Vicondoa, Pradip Fatehpuria
  • Patent number: 10293020
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogs of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 21, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP.
    Inventor: D. Travis Wilson
  • Patent number: 10279008
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 7, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10221213
    Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 5, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 10201585
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: February 12, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • Patent number: 10188693
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: January 29, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
  • Publication number: 20190023738
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 24, 2019
    Inventor: D. Travis Wilson